Keywords

drug interactions, HMG-CoA reductase inhibitors, myopathy, patient safety, pharmacology, rhabdomyolysis, statins

Authors

1. Finks, Shannon W. PharmD, FCCP, BCPS
2. Campbell, Jennifer D. PharmD, CDE

Abstract

Abstract: Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.